HDL biology remains highly relevant, but HDL-C alone should not be interpreted as a reliable marker of atheroprotection or as a therapeutic target. Very high HDL-C should not be used to downplay established causal risk factors. Future research should prioritize functional HDL metrics, deeper phenotyping, and mechanism-aligned trials to determine whether improving HDL quality, rather than simply raising HDL-C, can reduce ASCVD risk.
Building similarity graph...
Analyzing shared references across papers
Loading...
Paolo Parini
M Pedrelli
Current Opinion in Lipidology
Karolinska Institutet
Karolinska University Hospital
Integrated Cardio Metabolic Centre
Building similarity graph...
Analyzing shared references across papers
Loading...
Parini et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d895796c1944d70ce06864 — DOI: https://doi.org/10.1097/mol.0000000000001041